We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
ArthroCare has announced that a U.S. Court of Appeals for the Federal Circuit
affirmed in part a jury verdict in the company's patent infringement lawsuit
against Smith & Nephew.
The Centers for Medicare & Medicaid Services (CMS) clarified its payment
rules to present Medicare beneficiaries with the choice to receive presbyopia-correcting
intraocular lenses that provide restoration of distance, near and intermediate
vision with less dependency on eyeglasses or contact lenses following cataract
surgery.
New York Attorney General Eliot Spitzer has closed an investigation concerning
Johnson & Johnson's (J&J) marketing practices, the company announced
in its first quarter report filed with the SEC.
Two senior executives resigned from Theragenics May 8 over actions by the chief
executive that they considered inappropriate, the maker of cancer treatment
devices said.
Sky Holdings, listed on the AIM market of the London Stock Exchange, announced
that its 18 percent owned investment, Advanced Spinal Technologies (AST), has
received approval from the Western Institutional Review Board to commence clinical
trials for its Technology-Assisted Micro-Mobilization and Reflex Stimulator
(TAMARS) -- previously known as the pamm3 MicroManipulator.
Cancer researchers have long been seeking a test that would allow them to accurately
and easily diagnose ovarian cancer, one of the most lethal forms of the disease,
in the early stages when it is highly treatable.
Power3 Medical Products announced it has filed a provisional patent application
with the U.S. Patent and Trademark Office for the company's first generic, blood-based
diagnostic test for neuromuscular disorders such as ALS and Parkinson's disease.
Accuray has introduced the Xsight Spine Tracking System, which integrates with
the CyberKnife Stereotactic Radiosurgery System to eliminate the need for surgical
implantation of uncomfortable radiographic markers, or fiducials, in the delivery
of radiosurgery treatments for spinal tumors.
Hoji Alimi, founder and president of Oculus Innovative Sciences, announced that
the company has received its first 510(k) clearance from the FDA to market Dermacyn
Wound Care, formulated with Microcyn Technology, as a medical device for moistening,
lubricating and debriding of acute and traumatic wounds and burns.